stockrowVertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024.
- Revenue
- +11.9%
- EPS
- −39.2%
- Free cash flow
- −52.1%
Quarter to September 2026, against a year earlier
Follow VRTX
Alert me
Vertex Pharmaceuticals Incorporated (VRTX) Current ratio
Vertex Pharmaceuticals Incorporated's current ratio at the end of the quarter to 30 September 2026 was 2.3×, down 0.6× from fiscal 2025 (2.9×). Over the past ten years it has ranged from 2.3× (fiscal 2016) to 4.8× (fiscal 2022); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 2.9× | 7.76% |
| FY2024 | 2.7× | (32.48%) |
| FY2023 | 4.0× | (17.39%) |
| FY2022 | 4.8× | 8.14% |
| FY2021 | 4.5× | 3.03% |
| FY2020 | 4.3× | 19.90% |
| FY2019 | 3.6× | 5.32% |
| FY2018 | 3.4× | 4.54% |
| FY2017 | 3.3× | 41.99% |
| FY2016 | 2.3× | (16.87%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.3× | (26.63%) |
| Jun 2026 | 3.2× | 5.38% |
| Mar 2026 | 3.0× | 4.20% |
| Dec 2025 | 2.9× | 22.83% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 16.7× |
| RVMD Revolution Medicines, Inc. compare | 8.4× |
| ARGX argenex SE compare | 5.1× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 3.6× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 3.4× |
| GMAB Genmab A/S Sponsored ADR compare | 2.5× |
| VRTX Vertex Pharmaceuticals Incorporated | 2.3× |
| MRNA Moderna, Inc. compare | 2.3× |
| RPRX Royalty Pharma PLC compare | 1.3× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement